



# STIC Search Report

## Biotech-Chem Library

STIC Database | Tracking Number: 1741531

**TO:** Satyanarayana Gudibande  
**Location:** REM-3C04&3C18  
**Art Unit:** 1654  
**Wednesday, November 16, 2005**

**Case Serial Number:** 10/030944

**From:** Mary Hale  
**Location:** Biotech/Chem Library  
**Rem 1D86**  
**Phone:** 2-2507

**Mary.Hale@uspto.gov**

### Search Notes

Feel free to contact me if you have any questions.

Note -- results are printed on both sides of printout



This Page Blank (uspto)

Dudebande  
10/10 30944

Page 1

=> fil reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 12:08:55 ON 16 NOV 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2005 HIGHEST RN 868125-94-4  
DICTIONARY FILE UPDATES: 15 NOV 2005 HIGHEST RN 868125-94-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> e rgdldalrggg/sqep
E1          2      RGDL DALRG/SQEP
E2          1      RGDL DALRGG/SQEP
E3          2 --> RGDL DALRGGG/SQEP
E4          1      RGDL DALRGGGG/SQEP
E5          1      RGDL DALRGGGGG/SQEP
E6          1      RGDL DALRGGGGGG/SQEP
E7          1      RGDL DAVKGIPFYKGSRA/SQEP
E8          1      RGDL DGLR/SQEP
E9          2      RGDL DGLRGGG/SQEP
E10         6      RGDL DSLR/SQEP
E11         1      RGDL PLAARVAGR/SQEP
E12         1      RGDL FAVDTC/SQEP

=> s e3
      2 RGDL DALRGGG/SQEP
      85211 SQL=11
L1          2 (RGDL DALRGGG) /SQEP
```

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

(RGDLDALRGGG/SQEP AND SQL=11)

=> d 1-2 sqide can

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-74-8 REGISTRY  
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-  
α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 11  
NTE cyclic

SEQ 1 ALRGGGRGDL D  
===== =

HITS AT: 1-6, 7-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C43 H73 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAPplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-58-8 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-  
   α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 11  
 NTE cyclic

SEQ 1 ALRGGGRGDL D

=====

HITS AT: 1-6, 7-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C43 H73 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

=> fil medl,biosis,embase,capplus;s 11

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

20.47

SESSION

21.10

FILE 'MEDLINE' ENTERED AT 12:09:57 ON 16 NOV 2005

FILE 'BIOSIS' ENTERED AT 12:09:57 ON 16 NOV 2005  
 Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:09:57 ON 16 NOV 2005  
 Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:09:57 ON 16 NOV 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

L2 0 FILE MEDLINE  
 L3 0 FILE BIOSIS  
 L4 0 FILE EMBASE  
 L5 1 FILE CAPPLUS

TOTAL FOR ALL FILES

L6 1 L1

=> d ibib abs hitstr

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN /  
 ACCESSION NUMBER: 2001:45035 CAPLUS  
 DOCUMENT NUMBER: 134:86549  
 TITLE: Preparation of cyclic peptides for use as inhibitors /

of integrin  $\alpha v\beta 6$

**INVENTOR(S):** Jonczyk, Alfred; Diefenbach, Beate; Goodman, Simon  
**PATENT ASSIGNEE(S):** Merck Patent G.m.b.H., Germany  
**SOURCE:** Ger. Offen., 20 pp.  
**DOCUMENT TYPE:** Patent  
**LANGUAGE:** German  
**FAMILY ACC. NUM. COUNT:** 1  
**PATENT INFORMATION:**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19933173	A1	20010118	DE 1999-19933173	19990715
CA 2379022	AA	20010125	CA 2000-2379022	20000703
WO 2001005810	A2	20010125	WO 2000-EP6188	20000703
WO 2001005810	A3	20010517		
			W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
BR 2000012418	A	20020326	BR 2000-12418	20000703
EP 1196433	A2	20020417	EP 2000-943971	20000703
			R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	
JP 2003505395	T2	20030212	JP 2001-511467	20000703
AU 772782	B2	20040506	AU 2000-58236	20000703
NO 2002000176	A	20020114	NO 2002-176	20020114
ZA 2002001275	A	20030822	ZA 2002-1275	20020214
PRIORITY APPLN. INFO.:			DE 1999-19933173	A 19990715
			WO 2000-EP6188	W 20000703

OTHER SOURCE(S): MARPAT 134:86549

AB Title compds. cyclo(Arg-X1-Asp-X2-X3-X4-X5-X6-R1) [(I); X1 = Ser, Gly, Thr; X2 = Leu, Ile, Val, Phe; X3 = Asp, Glu, Lys, Phe; X4 = Gly, Ala, Ser; X5 = Leu, Ile, Nle, Val, Phe; X6 = Arg, Har, Lys; R1 = absent, one or more  $\omega$ -amino-carboxy acid residues; all amino acids may be either D- or L-configuration] were prepared using solid-phase peptide synthesis and tested for activity as integrin  $\alpha v\beta 6$  inhibitors for therapeutic use. Thus thirty-three I compds. were synthesized on chlorotriyl-polystyrol resin and tested for their binding capacities with the  $\alpha v\beta 6$  fibronectin receptor. Q-values for the tests (Q = IC50 I/IC50 reference peptide) (reference peptide =

Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-

NH2; 75 nM) ranged from 233 to 0.014.

IT 317366-58-8P 317366-74-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of cyclic peptides for use as inhibitors of integrin  $\alpha v\beta 6$  in treatment of)

RN 317366-58-8 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 317366-74-8 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



=> fil reg  
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
8.06	29.16

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-0.73	-0.73

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 12:10:19 ON 16 NOV 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2005 HIGHEST RN 868125-94-4  
DICTIONARY FILE UPDATES: 15 NOV 2005 HIGHEST RN 868125-94-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****  
*  
* The CA roles and document type information have been removed from *  
* the IDE default display format and the ED field has been added,      *  
* effective March 20, 2005. A new display format, IDERL, is now       *  
* available and contains the CA role and document type information. *  
*  
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s r[sgt]d[livxf] [dekf] [gas] [livxf] [rxk]/sqsp  
L7          294 R[SGT]D[LIXVF] [DEKF] [GAS] [LIXVF] [RXK] /SQSP  
  
=> s l7(l) (cyclo or cyclic)  
     3747558 CYCLO  
         38 CYCLOS  
     3747558 CYCLO  
         (CYCLO OR CYCLOS)  
     94190 CYCLIC  
L8          0 L7(L) (CYCLO OR CYCLIC)  
;  
  
=> s l7(l) (d or l)  
    7686897 D  
    1934043 L  
L9          0 L7(L) (D OR L)  
  
=> e rgldgldr/rggg/sqep 5  
E1          1      RGDLDAVKGIPFYKGSRA/SQEP  
E2          1      RGLDGLR/SQEP  
E3          2 --> RGLDGLRGGG/SQEP  
E4          6      RGDDLSLR/SQEP  
E5          1      RGDLEPLAARVAGR/SQEP  
  
=> s e3;e rgdlaalrggg/sqep 5  
    2 RGDLGLRGGG/SQEP  
    85211 SQL=11
```

L10           2 (RGDLGLRGGG) /SQEP  
              (RGDLGLRGGG/SQEP AND SQL=11)

E1           1     RGDLAAIVQRLSNRL/SQEP  
E2           1     RGDLAAIVQRLSNRLC/SQEP  
E3           1 --> RGDLAALRGGG/SQEP  
E4           1     RGDLAALSAPPV/SQEP  
E5           1     RGDLAFRDDSIPWPQEEPAIRPRSSQRVLPMGIQHSKELNRTCCLNGGACMLESFCACPPS  
              FYGRNCEHDVRKENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVA  
              SRTPELPPS/SQEP

=> s e3;e rtlddalrggg/sqep 5  
      1 RGDLAALRGGG/SQEP  
      85211 SQL=11

L11          1 (RGDLAALRGGG) /SQEP  
              (RGDLAALRGGG/SQEP AND SQL=11)

E1           2     RTDLDALR'OOA'/SQEP  
E2           2     RTDLDALR'OOA-OAA'/SQEP  
E3           2 --> RTDLDALRGGG/SQEP  
E4           2     RTDLDGLR/SQEP  
E5           2     RTDLDGLRGGG/SQEP

=> s e3;e rgdldalrxx/sqep 5  
      2 RTDLDALRGGG/SQEP  
      85211 SQL=11

L12          2 (RTDLDALRGGG) /SQEP  
              (RTDLDALRGGG/SQEP AND SQL=11)

E1           1     RGDLDALRGGGGG/SQEP  
E2           1     RGDLDALRGGGGGGG/SQEP  
E3           0 --> RGDLDALRXX/SQEP  
E4           1     RGDLDAVKGIPFYKGSRA/SQEP  
E5           1     RGDLDGLR/SQEP

=> e rgdldalr/sqep 5

E1           1     RGDLCQEWAISGCNTRCRGHHRQPCTHL/SQEP  
E2           1     RGDLD'BAL'LR/SQEP  
E3           2 --> RGDLDALR/SQEP  
E4           1     RGDLDALR'BAL-BAL'/SQEP  
E5           3     RGDLDALR'OOA'/SQEP

=> s e3

      2 RGDLDALR/SQEP  
      66848 SQL=8

L13          2 (RGDLDALR) /SQEP  
              (RGDLDALR/SQEP AND SQL=8)

=> e rtlddalr/sqep 5

E1           1     RTDLD'BAL'LR/SQEP  
E2           1     RTDLD'OAA'LR/SQEP  
E3           2 --> RTDLDALR/SQEP  
E4           2     RTDLDALR'OOA'/SQEP  
E5           2     RTDLDALR'OOA-OAA'/SQEP

=> s e3

      2 RTDLDALR/SQEP

```
66848 SQL=8
L14      2 (RTDLDALR)/SQEP
          (RTDLDALR/SQEP AND SQL=8)

=> e rtlddalra/sqep 5
E1      2 RTDLDALR'OOA'/SQEP
E2      2 RTDLDALR'OOA-OAA'/SQEP
E3      0 --> RTDLDALRA/SQEP
E4      2 RTDLDALRGGG/SQEP
E5      2 RTDLDGLR/SQEP

=> e rgdldalra/sqep 5
E1      3 RGDL DALR'OOA'/SQEP
E2      1 RGDL DALR'OOA-OAA'/SQEP
E3      0 --> RGDL DALRA/SQEP
E4      2 RGDL DALRG/SQEP
E5      1 RGDL DALRGG/SQEP


=> s l10 or l11 or l12 or l13 or l14
L15      9 L10 OR L11 OR L12 OR L13 OR L14

=> d 1-9 sqide can;fil caplus;s l15


L15 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 527744-99-6 REGISTRY
CN L-Argininamide, N2-acetyl-L-arginyglycyl-L- $\alpha$ -aspartyl-L-leucyl-D-
 $\alpha$ -aspartyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified
-----
type      ----- location -----      description
-----
terminal mod. Arg-1      -      N-acetyl
terminal mod. Arg-8      -      C-terminal amide
-----
SEQ      1 RGDL DALR
=====
HITS AT: 1-8
MF    C39 H69 N15 O13
SR    CA
LC    STN Files: CA, CAPLUS
DT.CA CAPplus document type: Conference
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.
```

PAGE 1-A



PAGE 1-B



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:385705

L15 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-75-9 REGISTRY  
 CN Cyclo(L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 11  
 NTE cyclic

SEQ 1 RGDLDGLRGG G  
 ===== =


HITS AT: 1-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*  
 MF C42 H71 N17 O15


SR CA  
LC STN Files: CA, CAPLUS  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-73-7 REGISTRY  
CN Cyclo(L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH

Page 15

SQL 11  
NTE cyclic

SEQ 1 RGDLDGLRGG G  
===== =  
HITS AT: 1-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C42 H71 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-67-9 REGISTRY  
CN Cyclo(D-alanyl-L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-  
arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 11  
NTE cyclic

SEQ 1 AALRGGRGD L  
===== =

HITS AT: 1-7, 8-11  
MF C42 H73 N17 O13

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549


L15 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-63-5 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-  
   α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 11  
 NTE cyclic

SEQ 1 ALRGGGRTDL D  
 ===== =  
 HITS AT: 1-6, 7-11


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*  
 MF C45 H77 N17 O16  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-61-3 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-  
 α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSearch  
 SQL 11  
 NTE cyclic

SEQ 1 ALRGGGRTDL D  
 ===== =  
 HITS AT: 1-6, 7-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C45 H77 N17 O16

SR CA


LC STN Files: CA, CAPLUS

DT CA Cplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)


1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-53-3 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 8  
 NTE cyclic

SEQ 1 ALRRGDLD  
 ======  
 HITS AT: 1-3, 4-8  
 MF C37 H64 N14 O12  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA Caplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)




1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-50-0 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 8  
 NTE cyclic

SEQ 1 ALRRTDLD  
 ======  
 HITS AT: 1-3, 4-8  
 MF C39 H68 N14 O13  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA Caplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549


L15 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 313246-44-5 REGISTRY  
 CN L-Argininamide, N<sub>2</sub>-acetyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 8  
 NTE modified

type	-----	location	-----	description
terminal mod.	Arg-1	-		N-acetyl
terminal mod.	Arg-8	-		C-terminal amide


SEQ 1 RTDLDALR  
 ======  
 HITS AT: 1-8  
 MF C41 H73 N15 O14  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA CAPplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:42449

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	141.87	171.03
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.73

FILE 'CAPLUS' ENTERED AT 12:16:33 ON 16 NOV 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Nov 2005 VOL 143 ISS 21  
FILE LAST UPDATED: 15 Nov 2005 (20051115/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

✓8/13/05/18/23

V30

L16                   3 L15


=> d 1-3 ibib abs hitseq

L16 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2002:692564 CAPLUS  
DOCUMENT NUMBER: 138:385705  
TITLE: Linear and cyclic peptides for integrin  
αvβ6 inhibition  
AUTHOR(S): Zischinsky, Gunther; Groth, Ulrich; Diefenbach, Beate;  
              Jonczyk, Alfred  
CORPORATE SOURCE: Faculty of Chemistry, University of Konstanz, Germany  
SOURCE: Peptides: The Wave of the Future, Proceedings of the  
Second International and the Seventeenth American  
Peptide Symposium, San Diego, CA, United States, June  
9-14, 2001 (2001), 733-734. Editor(s): Lebl, Michal;  
Houghten, Richard A. American Peptide Society: San  
Diego, Calif.  
CODEN: 69DBAL; ISBN: 0-9715560-0-8  
DOCUMENT TYPE: Conference  
LANGUAGE: English  
AB A symposium report. Integrin αvβ6 inhibitory activity of  
peptides was enhanced by cyclization, which increased rigidity and  
proteolytic stability. The best linear derivative was the non-RGD peptide  
Ac-TRDLDsLR-NH2. Selected cyclic peptides proved to be stable in human  
blood plasma with half life-times of more than 30 h.  
IT 527744-99-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
          (linear and cyclic peptides as inhibitors of integrin αvβ6)  
RN 527744-99-6 CAPLUS  
CN L-Argininamide, N2-acetyl-L-arginyglycyl-L-α-aspartyl-L-leucyl-D-  
      α-aspartyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)  
NTE modified  
SEQ 1 RGDLDALR


Appenzel

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:45035 CAPLUS  
 DOCUMENT NUMBER: 134:86549  
 TITLE: Preparation of cyclic peptides for use as inhibitors of integrin  $\alpha v \beta 6$   
 INVENTOR(S): Jonczyk, Alfred; Diefenbach, Beate; Goodman, Simon  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: Ger. Offen., 20 pp.  
 CODEN: GWXXBX

1/11/1

DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19933173	A1	20010118	DE 1999-19933173	19990715
CA 2379022	AA	20010125	CA 2000-2379022	20000703
WO 2001005810	A2	20010125	WO 2000-EP6188	20000703

WO 2001005810	A3	20010517		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000012418	A	20020326	BR 2000-12418	20000703
EP 1196433	A2	20020417	EP 2000-943971	20000703
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2003505395	T2	20030212	JP 2001-511467	20000703
AU 772782	B2	20040506	AU 2000-58236	20000703
NO 2002000176	A	20020114	NO 2002-176	20020114
ZA 2002001275	A	20030822	ZA 2002-1275	20020214
PRIORITY APPLN. INFO.:			DE 1999-19933173	A 19990715
			WO 2000-EP6188	W 20000703

OTHER SOURCE(S) : MARPAT 134:86549

AB Title compds. cyclo(Arg-X1-Asp-X2-X3-X4-X5-X6-R1) [(I); X1 = Ser, Gly, Thr; X2 = Leu, Ile, Nle, Val, Phe; X3 = Asp, Glu, Lys, Phe; X4 = Gly, Ala, Ser; X5 = Leu, Ile, Nle, Val, Phe; X6 = Arg, Har, Lys; R1 = absent, one or more  $\omega$ -amino-carboxy acid residues; all amino acids may be either D- or L-configuration] were prepared using solid-phase peptide synthesis and tested for activity as integrin  $\alpha v \beta 6$  inhibitors for therapeutic use. Thus thirty-three I compds. were synthesized on chlorotriptyl-polystyrol resin and tested for their binding capacities with the  $\alpha v \beta 6$  fibronectin receptor. Q-values for the tests (Q = IC50 I/IC50 reference peptide) (reference peptide =

Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-

NH2; 75 nM) ranged from 233 to 0.014.

IT 317366-50-0P 317366-53-3P 317366-61-3P  
317366-63-5P 317366-67-9P 317366-73-7P  
317366-75-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of cyclic peptides for use as inhibitors of integrin  $\alpha v \beta 6$  in treatment of)


RN 317366-50-0 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRRTDLD

Absolute stereochemistry.




RN 317366-53-3 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginyllglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRRGDLD



RN 317366-61-3 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyllglycylglycylglycyl-L-arginyll-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGGRTDL D

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-63-5 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGGRTDL D

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-67-9 CAPLUS


CN Cyclo(D-alanyl-L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-α-aspartyl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 AALRGGGRGD L

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-73-7 CAPLUS


CN Cyclo(L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 RGDLGGLRGG G

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-75-9 CAPLUS


CN Cyclo(L-arginylglycyl-L-α-aspartyl-L-leucyl-L-α-aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 RGDLGLRG G

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L16 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2000:909678 CAPLUS  
 DOCUMENT NUMBER: 134:42449  
 TITLE: Synthesis of peptide inhibitors of integrin  $\alpha\beta\beta_6$   
 INVENTOR(S): Jonczyk, Alfred; Diefenbach, Beate; Groth, Ulrich;  
 Zischinsky, Gunther  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: Ger. Offen., 34 pp.  
 CODEN: GWXXBX

*Amplified*

DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

DE 19929410	A1	20001228	DE 1999-19929410	19990626
CA 2377224	AA	20010104	CA 2000-2377224	20000613
WO 2001000660	A1	20010104	WO 2000-EP5404	20000613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1189930	A1	20020327	EP 2000-949177	20000613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000011954	A	20020507	BR 2000-11954	20000613
JP 2003503422	T2	20030128	JP 2001-507066	20000613
AU 771099	B2	20040311	AU 2000-62630	20000613
NO 2001006341	A	20020225	NO 2001-6341	20011221
ZA 2002000673	A	20030424	ZA 2002-673	20020124
PRIORITY APPLN. INFO.: DE 1999-19929410 A 19990626 WO 2000-EP5404 W 20000613				

OTHER SOURCE(S): MARPAT 134:42449

AB The invention describes the solid-phase synthesis of peptides H3CC(O)-Arg-X1-Asp-X2-X3-X4-X5-X6-NH<sub>2</sub> [(I); X1 = Ser, Gly, Thr, Asp, Arg, Val, Tyr, His or Ala; X2 = Leu, Ile, Nle, Val or Phe; X3 = Asp, Glu, Lys, Phe, Aib, Nal, Gly, Ala, Bgl or Phg; X4 = Gly, Ala, Ser, βAla or αAbu; X5 = Leu, Ile, Nle, Val, Phe; X6 = Arg, Har, Lys, Leu, Orn, Phe, Ala, Tyr, Gly, Ser or Asp] for use as inhibitors of αvβ6 integrin in the treatment of disease. Thus I [X1 = Gly; X2 = Leu; X3 = D-Asp; X4 = Ser; X5 = Leu; X6 = Arg (II)] was synthesized using solid-phase techniques. In in vitro binding tests, using peptide H3CC(O)-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-NH<sub>2</sub> as standard, II had Q-value (IC50 test peptide/IC50 standard) 0.15 at 75 nM.

IT 313246-44-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptide inhibitors of integrin αvβ6 for treatment of disease)

RN 313246-44-5 CAPLUS


CN L-Argininamide, N<sub>2</sub>-acetyl-L-arginyl-L-threonyl-L-α-aspartyl-L-leucyl-L-α-aspartyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

NTE modified


SEQ 1 RTDLDALR

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



=&gt; dis his

(FILE 'HOME' ENTERED AT 12:06:59 ON 16 NOV 2005)

FILE 'REGISTRY' ENTERED AT 12:08:55 ON 16 NOV 2005  
E RGDL DALRGGG/SQEP

L1 2 S E3

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 12:09:57 ON 16 NOV 2005  
L2 0 FILE MEDLINE  
L3 0 FILE BIOSIS  
L4 0 FILE EMBASE  
L5 1 FILE CAPLUS  
TOTAL FOR ALL FILES  
L6 1 S L1FILE 'REGISTRY' ENTERED AT 12:10:19 ON 16 NOV 2005  
L7 294 S R[SGT]D[LIXVF] [DEKF] [GAS] [LIXVF] [RXK]/SQSP

L8 0 S L7 (L) (CYCLO OR CYCLIC)  
L9 0 S L7 (L) (D OR L)  
E RGDLGLRGGG/SQEP 5  
L10 2 S E3  
E RGDLAALRGGG/SQEP 5  
L11 1 S E3  
E RTDLDALRGGG/SQEP 5  
L12 2 S E3  
E RGDL DALRXX/SQEP 5  
E RGDL DALR/SQEP 5  
L13 2 S E3  
E RTDLDALR/SQEP 5  
L14 2 S E3  
E RTDLDALRA/SQEP 5  
E RGDL DALRA/SQEP 5  
L15 9 S L10 OR L11 OR L12 OR L13 OR L14

FILE 'CAPLUS' ENTERED AT 12:16:33 ON 16 NOV 2005  
L16 3 S L15

=> log y		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		28.86	199.89
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		SINCE FILE	TOTAL
CA SUBSCRIBER PRICE		ENTRY	SESSION
		-2.19	-2.92

STN INTERNATIONAL LOGOFF AT 12:17:14 ON 16 NOV 2005

Page 1

=> s r[sgt]d[lixfvf] [dekf] [gas] [lixfvf] [rxk]/sqsp  
L1 296 R [SGT]D [LIXVF] [DEKF] [GAS] [LIXVF] [RXK] /SQSP

=> s cyclic/note  
L2 27096 CYCLIC/NTE

=> s l1 and l2  
L3 30 L1 AND L2

=> d 1-30 sqide can

L3 ANSWER 1 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-80-6 REGISTRY  
CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-4-aminobutanoyl-L-  
arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI)  
(CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 10  
NTE cyclic


-----  
type ----- location ----- description  
-----  
uncommon Oaa-4 - -  
uncommon Oaa-5 - -  
-----


SEQ 1 ALRXXRTDLD  
====  
HITS AT: 1-3, 6-10

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*  
MF C47 H82 N16 O15  
SR CA  
LC STN Files: CA, CAPLUS  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 2 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-79-3 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-6-aminohexanoyl-L-  
 arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI)  
 (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 10  
 NTE **cyclic**

---

type	----- location -----	description
uncommon	Oaa-4	-
uncommon	Oaa-5	-


---

SEQ 1 ALRXXRTDLD  
 =====  
 HITS AT: 1-3, 6-10


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*  
 MF C51 H90 N16 O15  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 3 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-78-2 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-L-arginylglycyl-L-  
   α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 9  
 NTE cyclic

type	location	description
uncommon	Oaa-4	-

SEQ 1 ALRXRGDLD  
 =====  
 HITS AT: 1-3, 5-9

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


MF C41 H71 N15 O13

SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 4 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-77-1 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-L-arginyl-L-threonyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 9

NTE cyclic

type	-----	location	-----	description
uncommon	Oaa-4	-	-	

SEQ 1 ALRXRTDLD

==== =====

HITS AT: 1-3, 5-9

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C43 H75 N15 O14

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-76-0 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-amino hexanoyl-L-arginyl-L-threonyl-L-  
   α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSearch  
 SQL 9  
 NTE cyclic

type	location	description
uncommon	Oaa-4	-

SEQ 1 ALRXRTDLD  
 =====  
 HITS AT: 1-3, 5-9

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C45 H79 N15 O14

SR CA


LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-75-9 REGISTRY

CN Cyclo(L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 11  
NTE cyclic

SEQ 1 RGDLDGLRGG G

三三三三三

HITS AT: 1-8

**\*\*RELATED SEQUENCES AVAILABLE WITH SEOLINK\*\***

MF C42 H71 N17 O15

SR CA


LC STN Files: CA, CAPLUS

PT.CA CAPplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

## Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 7 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-74-8 REGISTRY  
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-  
α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 11  
NTE cyclic


SEQ 1 ALRGGGRGDL D  
==== =  
HITS AT: 1-3, 7-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


MF C43 H73 N17 O15  
SR CA  
LC STN Files: CA, CAPLUS  
DT.CA Cplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 8 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-73-7 REGISTRY  
 CN Cyclo(L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 11  
 NTE cyclic

SEQ 1 RGDLGLRGG G

=====

HITS AT: 1-8

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C42 H71 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 9 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-72-6 REGISTRY  
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycylglycyl-L-  
arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA  
INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 13

NTE cyclic

SEQ 1 ALRGGGGGRG DLD  
=====

HITS AT: 1-3, 9-13

MF C47 H79 N19 O17

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 10 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-71-5 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 12  
 NTE **cyclic**

SEQ 1 ALRGGGGRGD LD  
 === == =

HITS AT: 1-3, 8-12

MF C45 H76 N18 O16

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 11 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-70-4 REGISTRY  
 CN Cyclo[[2-(2-aminoethoxy)ethoxy]acetyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl-L-alanyl-L-leucyl-L-arginyl] (9CI) (CA INDEX  
 NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 9  
 NTE cyclic

---

type	----- location -----	description
------	----------------------	-------------

**uncommon**                    **Oaa-4**                    -                    -  
**stereo**                    **Asp-9**                    -                    D

SEQ 1 ALRXRGDLD

— — —

HITS AT: 1-3, 5-9

**\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\***

MF C43 H75 N15 O15

SR CA


LC STN Files: CA, CAPLUS

DT-CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

## Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 12 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-69-1 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-L-arginylglycyl-L-  
   α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 9  
 NTE cyclic

type	----- location -----	description
uncommon	Oaa-4	-

SEQ 1 ALRXRGDLD  
 =====

HITS AT: 1-3, 5-9

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C43 H75 N15 O13

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 13 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-68-0 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminoheptanoyl-6-aminoheptanoyl-L-


arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA  
INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 10  
NTE cyclic

type	----- location -----	description
uncommon	Oaa-4	-
uncommon	Oaa-5	-


SEQ 1 ALRXXRGDLD  
===== HITS AT: 1-3, 6-10  
MF C49 H86 N16 O14  
SR CA  
LC STN Files: CA, CAPLUS  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 134:86549

L3 ANSWER 14 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-65-7 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 9  
 NTE cyclic

SEQ 1 ALRGRGDLD  
 =====  
 HITS AT: 1-3, 5-9

## \*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C39 H67 N15 O13  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549


L3 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-64-6 REGISTRY  
CN Cyclo(L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 11  
NTE cyclic

SEQ 1 RGGGRTDLDG L  
= ===== =  
HITS AT: 1, 5-11


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*  
MF C44 H75 N17 O16  
SR CA  
LC STN Files: CA, CAPLUS  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 16 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-63-5 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-  
   α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 11  
 NTE cyclic

SEQ       1 ALRGGGRTDL D  
       ====   ===== =  
 HITS AT:  1-3, 7-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C45 H77 N17 O16

SR CA


LC STN Files: CA, CAPLUS

DT CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-62-4 REGISTRY

CN Cyclo(L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-

L-leucyl-D- $\alpha$ -aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 11  
NTE cyclic


SEQ 1 RGGGRTDLDG L  
= ===== =  
HITS AT: 1, 5-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


MF C44 H75 N17 O16  
SR CA  
LC STN Files: CA, CAPLUS  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-61-3 REGISTRY  
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-  
α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 11  
NTE cyclic

SEQ 1 ALRGGGRTDL D  
=====

HITS AT: 1-3, 7-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C45 H77 N17 O16

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549


L3 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-60-2 REGISTRY  
 CN Cyclo( $\beta$ -alanyl- $\beta$ -alanyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl-L-alanyl-L-leucyl-L-arginyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 10  
 NTE cyclic

type	-----	location	-----	description
uncommon	Bal-4	-	-	
uncommon	Bal-5	-	-	


SEQ 1 ALRXXRGDLD  
 =====  
 HITS AT: 1-3, 6-10  
 MF C43 H74 N16 O14  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 20 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-59-9 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycylglycylglycyl-L-  
 arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA  
 INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 14  
 NTE cyclic

SEQ 1 ALRGGGGGGR GDLD  
 === = ====  
 HITS AT: 1-3, 10-14  
 MF C49 H82 N20 O18

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-58-8 REGISTRY  
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-  
α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 11  
NTE **cyclic**


SEQ 1 ALRGGGRGDL D  
===== =  
HITS AT: 1-3, 7-11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


MF C43 H73 N17 O15  
SR CA  
LC STN Files: CA, CAPLUS  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549


L3 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-57-7 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 10  
 NTE cyclic

SEQ 1 ALRGGRGDLD


=====  
HITS AT: 1-3, 6-10  
MF C41 H70 N16 O14  
SR CA  
LC STN Files: CA, CAPLUS  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549


L3 ANSWER 23 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-56-6 REGISTRY  
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 9  
 NTE cyclic

SEQ 1 ALRGRGDLD  
 =====  
 HITS AT: 1-3, 5-9

## \*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C39 H67 N15 O13  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA Caplus document type: Conference; Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)  
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)



2 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:385705


REFERENCE 2: 134:86549

L3 ANSWER 24 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-54-4 REGISTRY  
 CN Cyclo(L-arginyl-L-arginylglycyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 8  
 NTE cyclic

SEQ 1 RRGDLDGL  
 =====

HITS AT: 1, 2-8  
 MF C36 H62 N14 O12  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA Caplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES

(Uses)




1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 25 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-53-3 REGISTRY  
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 8  
 NTE cyclic

SEQ 1 ALRRGDLD  
 ======  
 HITS AT: 1-3, 4-8  
 MF C37 H64 N14 O12  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA CAPplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
 (Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549


L3 ANSWER 26 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-52-2 REGISTRY  
 CN Cyclo(L-arginyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 8  
 NTE cyclic

SEQ 1 RRGDLDSL  
 =====

HITS AT: 1, 2-8

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C37 H64 N14 O13  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA CAPplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 27 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-51-1 REGISTRY  
 CN Cyclo(L-arginyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 8  
 NTE cyclic

SEQ 1 RRGDLDSL  
 =====

HITS AT: 1, 2-8


## \*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C37 H64 N14 O13

SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 28 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-50-0 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 8

NTE cyclic

SEQ 1 ALRRTDLD

=====

HITS AT: 1-3, 4-8

MF C39 H68 N14 O13


SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 29 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 317366-49-7 REGISTRY  
 CN Cyclo(L-arginyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 8  
 NTE cyclic


SEQ 1 RRTDLDLSL  
 =====

HITS AT: 1, 2-8

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C39 H68 N14 O14  
 SR CA  
 LC STN Files: CA, CAPLUS  
 DT.CA CAplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 30 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 317366-48-6 REGISTRY  
CN Cyclo(L-arginyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 8  
NTE cyclic


SEQ 1 RRTDLDLSL  
=====

HITS AT: 1, 2-8

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF C39 H68 N14 O14  
SR CA  
LC STN Files: CA, CAPLUS  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

• => fil medl,biosis,embase,capplus;	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	224.79	225.00

FILE 'MEDLINE' ENTERED AT 08:33:23 ON 30 NOV 2005

FILE 'BIOSIS' ENTERED AT 08:33:23 ON 30 NOV 2005  
 Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 08:33:23 ON 30 NOV 2005  
 Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 08:33:23 ON 30 NOV 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

```
=> s zischinsky g?/au;s groth u?/au;s diefenbach b?/au;s jonczyk a?/au
L4          0 FILE MEDLINE
L5          0 FILE BIOSIS
L6          0 FILE EMBASE
L7          8 FILE CAPPLUS
```

TOTAL FOR ALL FILES  
 L8 8 ZISCHINSKY G?/AU

```
L9          28 FILE MEDLINE
L10         56 FILE BIOSIS
L11         33 FILE EMBASE
L12         89 FILE CAPPLUS
```

TOTAL FOR ALL FILES  
L13 206 GROTH U?/AU

L14 10 FILE MEDLINE  
L15 22 FILE BIOSIS  
L16 9 FILE EMBASE  
L17 44 FILE CAPLUS

TOTAL FOR ALL FILES  
L18 85 DIEFENBACH B?/AU

L19 34 FILE MEDLINE  
L20 71 FILE BIOSIS  
L21 72 FILE EMBASE  
L22 270 FILE CAPLUS

TOTAL FOR ALL FILES  
L23 447 JONCZYK A?/AU

=> s l8 and l13 and l18 and l23  
L24 0 FILE MEDLINE  
L25 0 FILE BIOSIS  
L26 0 FILE EMBASE  
L27 4 FILE CAPLUS

TOTAL FOR ALL FILES  
L28 4 L8 AND L13 AND L18 AND L23

=> s l3 not l28  
L29 0 FILE MEDLINE  
L30 0 FILE BIOSIS  
L31 0 FILE EMBASE  
L32 1 FILE CAPLUS

TOTAL FOR ALL FILES  
L33 1 L3 NOT L28

=> d ibib abs hitseq

L33 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:45035 CAPLUS  
DOCUMENT NUMBER: 134:86549  
TITLE: Preparation of cyclic peptides for use as inhibitors  
of integrin  $\alpha v \beta 6$   
INVENTOR(S): Jonczyk, Alfred; Diefenbach, Beate; Goodman, Simon  
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
SOURCE: Ger. Offen., 20 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

DE 19933173	A1	20010118	DE 1999-19933173	19990715
CA 2379022	AA	20010125	CA 2000-2379022	20000703
WO 2001005810	A2	20010125	WO 2000-EP6188	20000703
WO 2001005810	A3	20010517		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012418	A	20020326	BR 2000-12418	20000703
EP 1196433	A2	20020417	EP 2000-943971	20000703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003505395	T2	20030212	JP 2001-511467	20000703
AU 772782	B2	20040506	AU 2000-58236	20000703
NO 2002000176	A	20020114	NO 2002-176	20020114
ZA 2002001275	A	20030822	ZA 2002-1275	20020214
PRIORITY APPLN. INFO.: DE 1999-19933173 A 19990715 WO 2000-EP6188 W 20000703				

OTHER SOURCE(S) : MARPAT 134:86549

AB Title compds. cyclo(Arg-X1-Asp-X2-X3-X4-X5-X6-R1) [(I); X1 = Ser, Gly, Thr; X2 = Leu, Ile, Nle, Val, Phe; X3 = Asp, Glu, Lys, Phe; X4 = Gly, Ala, Ser; X5 = Leu, Ile, Nle, Val, Phe; X6 = Arg, Har, Lys; R1 = absent, one or more  $\omega$ -amino-carboxy acid residues; all amino acids may be either D- or L-configuration] were prepared using solid-phase peptide synthesis and tested for activity as integrin  $\alpha v \beta 6$  inhibitors for therapeutic use. Thus thirty-three I compds. were synthesized on chlorotriyl-polystyrol resin and tested for their binding capacities with the  $\alpha v \beta 6$  fibronectin receptor. Q-values for the tests (Q = IC50 I/IC50 reference peptide) (reference peptide =

Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-

NH2; 75 nM) ranged from 233 to 0.014.

IT 317366-48-6P 317366-49-7P 317366-50-0P  
317366-51-1P 317366-52-2P 317366-53-3P  
317366-54-4P 317366-56-6P 317366-57-7P  
317366-58-8P 317366-59-9P 317366-60-2P  
317366-61-3P 317366-62-4P 317366-63-5P  
317366-64-6P 317366-65-7P 317366-68-0P  
317366-69-1P 317366-70-4P 317366-71-5P  
317366-72-6P 317366-73-7P 317366-74-8P  
317366-75-9P 317366-76-0P 317366-77-1P  
317366-78-2P 317366-79-3P 317366-80-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of cyclic peptides for use as inhibitors of integrin  $\alpha v \beta 6$  in treatment of)


RN 317366-48-6 CAPLUS

CN Cyclo(L-arginyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RRTDLDLSL

Absolute stereochemistry.




RN 317366-49-7 CAPLUS

CN Cyclo(L-arginyl-L-arginyll-threonyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RRTDLDLSL

Absolute stereochemistry.




RN 317366-50-0 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginyll-arginyl-L-threonyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRRRTDLD

Absolute stereochemistry.




RN 317366-51-1 CAPLUS

CN Cyclo(L-arginyl-L-arginylglycyl-L-alpha-aspartyl-L-leucyl-L-alpha-aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RRGDLDSL




RN 317366-52-2 CAPLUS

CN Cyclo(L-arginyl-L-arginylglycyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RRGDLDSL




RN 317366-53-3 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRRGDLD




RN 317366-54-4 CAPLUS

CN Cyclo(L-arginyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RRGDLDGL




RN 317366-56-6 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRGRGDLD



RN 317366-57-7 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGRGDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-58-8 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEO 1 ALRGGGRGDL D

## Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 317366-59-9 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycylglycylglycylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 ALRGGGGGGR GDLD

## Absolute stereochemistry.

PAGE 1-A






RN 317366-60-2 CAPLUS


CN Cyclo(β-alanyl-β-alanyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl-L-alanyl-L-leucyl-L-arginyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRXXRGDLD

Absolute stereochemistry.






RN 317366-61-3 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 ALRGGGRTDL D

Absolute stereochemistry.



PAGE 1-B



RN 317366-62-4 CAPLUS


CN Cyclo(L-arginyllglycylglycylglycyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 RGGGRTDLDG L

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-63-5 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-alpha-aspartyl-L-leucyl-L-alpha-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGGRTDL D

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-64-6 CAPLUS


CN Cyclo(L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 RGGGRTDLDG L

Absolute stereochemistry.

PAGE 1-A






RN 317366-65-7 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycyl-L-arginylglycyl-L-alpha-aspartyl-L-leucyl-L-alpha-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRGRGDLD



RN 317366-68-0 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-6-aminohexanoyl-L-arginylglycyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXXRGDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-69-1 CAPPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminoheptanoyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXRGDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-70-4 CAPLUS


CN Cyclo[[2-(2-aminoethoxy)ethoxy]acetyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl-L-alanyl-L-leucyl-L-arginyl] (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXRGDLD


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 317366-71-5 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 ALRGGGGRGD LD

Absolute stereochemistry.



PAGE 1-B



RN 317366-72-6 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycyl-L-  
arginylglycyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl) (9CI) (CA  
INDEX NAME)

NTE cyclic


SEQ 1 ALRGGGGGRG DLD

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 317366-73-7 CAPLUS


CN Cyclo(L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 RGDLGGLRGG G

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-74-8 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-alpha-aspartyl-L-leucyl-L-alpha-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGGRGDL D

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 317366-75-9 CAPLUS


CN Cyclo(L-arginylglycyl-L- $\alpha$ -aspartyl-L-leucyl-L- $\alpha$ -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 RGDLDGLRGG G

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-76-0 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohecanoyl-L-arginyl-L-threonyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXRTDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-77-1 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-L-arginyl-L-threonyl-L- $\alpha$ -aspartyl-L-leucyl-D- $\alpha$ -aspartyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 ALRXRTDLD

Absolute stereochemistry.

PAGE 1-A






RN 317366-78-2 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-L-arginylglycyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRXRGDLD



RN 317366-79-3 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-6-aminohexanoyl-L-arginyl-L-threonyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXXRTDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-80-6 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-4-aminobutanoyl-L-arginyl-L-threonyl-L-alpha-aspartyl-L-leucyl-D-alpha-aspartyl) (9CI)  
(CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXXRTDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=> s 13 not (18 or 113 or 118 or 123)

L34 0 FILE MEDLINE  
 L35 0 FILE BIOSIS  
 L36 0 FILE EMBASE  
 L37 0 FILE CAPLUS

TOTAL FOR ALL FILES

L38 0 L3 NOT (L8 OR L13 OR L18 OR L23)

=> dis his

(FILE 'HOME' ENTERED AT 08:31:16 ON 30 NOV 2005)

FILE 'REGISTRY' ENTERED AT 08:31:25 ON 30 NOV 2005  
 L1 296 S R[SGT]D[LIXVF] [DEKF] [GAS] [LIXVF] [RXK] /SQSP  
 L2 27096 S CYCLIC/NTE  
 L3 30 S L1 AND L2

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 08:33:23 ON 30 NOV 2005

L4 0 FILE MEDLINE  
L5 0 FILE BIOSIS  
L6 0 FILE EMBASE  
L7 8 FILE CAPLUS  
TOTAL FOR ALL FILES  
L8 8 S ZISCHINSKY G?/AU  
L9 28 FILE MEDLINE  
L10 56 FILE BIOSIS  
L11 33 FILE EMBASE  
L12 89 FILE CAPLUS  
TOTAL FOR ALL FILES  
L13 206 S GROTH U?/AU  
L14 10 FILE MEDLINE  
L15 22 FILE BIOSIS  
L16 9 FILE EMBASE  
L17 44 FILE CAPLUS  
TOTAL FOR ALL FILES  
L18 85 S DIEFENBACH B?/AU  
L19 34 FILE MEDLINE  
L20 71 FILE BIOSIS  
L21 72 FILE EMBASE  
L22 270 FILE CAPLUS  
TOTAL FOR ALL FILES  
L23 447 S JONCZYK A?/AU  
L24 0 FILE MEDLINE  
L25 0 FILE BIOSIS  
L26 0 FILE EMBASE  
L27 4 FILE CAPLUS  
TOTAL FOR ALL FILES  
L28 4 S L8 AND L13 AND L18 AND L23  
L29 0 FILE MEDLINE  
L30 0 FILE BIOSIS  
L31 0 FILE EMBASE  
L32 1 FILE CAPLUS  
TOTAL FOR ALL FILES  
L33 1 S L3 NOT L28  
L34 0 FILE MEDLINE  
L35 0 FILE BIOSIS  
L36 0 FILE EMBASE  
L37 0 FILE CAPLUS  
TOTAL FOR ALL FILES  
L38 0 S L3 NOT (L8 OR L13 OR L18 OR L23)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.08	249.08
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

STN INTERNATIONAL LOGOFF AT 08:36:47 ON 30 NOV 2005